Tag: OTCBB:ELTP

  • Stocks In News: Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (ADR) (NYSE:GSK), Elite Pharmaceuticals Inc (OTCBB:ELTP), VIVUS (NASDAQ:VVUS), Eisai Co., Ltd (ADR) (OTCMKTS:ESALY)

    The Russian unit of US cosmetic giant Johnson & Johnson (NYSE:JNJ) has contested the 100,000 rubles ($2,925) fine imposed by the Federal Anti-monopoly Service in the Moscow Commercial Court, the court told RIA Novosti. Johnson & Johnson (NYSE:JNJ) net profit margin is 20.90% and weekly performance is -0.22%. On last trading day company shares ended up $105.42. Analysts mean target price for the company is $105.02. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average is 3.57%.

    The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline’s (LSE: GSK) Mekinist(trametinib) as a single agent in the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.GlaxoSmithKline plc (ADR) (NYSE:GSK) shares advanced 0.41% in last trading session and ended the day on $54.52. GSK Gross Margin is 69.60% and its return on assets is 17.30%. GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is 4.62%.

    Elite Pharmaceuticals Inc (OTCBB:ELTP) , a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2014 (“Fiscal 2014”). Elite Pharmaceuticals Inc (OTCBB:ELTP) shares moved up 1.54% in last trading session and was closed at $0.395, while trading in range of $0.37-$0.40.

    Analysts at Zacks upgraded shares of VIVUS from a “neutral” rating to an “outperform” rating in a research note on Tuesday. They now have a $5.70 price target on the stock. VIVUS, Inc. (NASDAQ:VVUS) ended the last trading day at $5.29. Company weekly volatility is calculated as 3.13% and price to cash ratio as 1.73. VIVUS, Inc. (NASDAQ:VVUS) showed a positive weekly performance of 4.34%.

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has launched its Chocola BB Royal Drink in China. This marks the first Chocola BB series product launched in China by Eisai. In addition to including the ingredients that have long been the foundation of the Chocola BB brand in Japan, such as vitamin B6, nicotinamide, royal jelly and taurine to support consumers’ beauty and wellness, Chocola BB Royal Drink also specially contains collagen, L-carnitine, coix seed, polygonatum rhizome and goji berry to specifically address the needs of consumers in China. It also features an easy-to-drink pineapple flavor and is low in calories with approximately 9 kcal per bottle. Eisai Co., Ltd (ADR) (OTCMKTS:ESALY) On last trading day company shares ended up $41.63.